Navigation Links
Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug
Date:1/28/2009

What separates the few cancer cells that survive chemotherapy leaving the door open to recurrence from those that don't? Weizmann Institute scientists developed an original method for imaging and analyzing many thousands of living cells to reveal exactly how a chemotherapy drug affects each one.

For research student Ariel Cohen, together with Naama Geva-Zatorsky and Eran Eden in the lab of Prof. Uri Alon of the Institute's Molecular Cell Biology Department, the question posed an interesting challenge. To approach it, they needed a method that would allow them to cast a wide net on the one hand to sift through the numerous cellular proteins that could conceivably affect survival but that would let them zoom in on the activities of individual cells in detail, on the other. Letting the computer take over the painstaking work of searching for anomalies enabled the team to look at the behavior of over 1000 different proteins. Even so, it took several years to complete the project, which entailed tagging the specific proteins in each group of cancer cells with a fluorescent gene and capturing a series of time-lapse images over 72 hours. A second, fainter fluorescent marker was added to outline the cells, so the computer could identify them. A chemotherapy drug was introduced 24 hours into this period, after which the cells began the process of either dying or defending themselves against the drug.

The team's efforts have produced a comprehensive library of tagged cells, images and data on cancer cell proteins a virtual goldmine of ready material for further cancer research. And they succeeded in pinpointing two proteins that seem to play a role in cancer cell survival.

Although most of the proteins behaved similarly in all the cells, the researchers found that a small subset of them around five percent could act unpredictably, even when the cells and drug exposure were identical. The scientists called these proteins bimodal, as they acted in one of two ways.

The team then asked whether any of the bimodal proteins they had identified were those that occasionally promote cell survival. They found two molecules that seem to fit the bill. One of them, known by the letters DDX5, is a multitasking protein that, among other things, plays a role in initiating the production of other proteins. The other, RFC1, also plays varied roles, including directing the repair of damaged DNA. When the researchers blocked the production of these proteins in the cancer cells, the drug became much more efficient at wiping out the growth.

Cohen: 'This method gave us tremendous insight into how a cell responds to a drug. By conducting an unbiased study we started with no preconceived notions of which proteins were involved we were able to pinpoint possible new drug targets and to see how certain activities might boost the effectiveness of current drugs.'


'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related biology news :

1. Weizmann Institute scientists discover: A risk distribution law for evolution
2. Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
3. The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes
4. DOE Joint Genome Institute completes soybean genome
5. Stowers Institutes Baumann Lab identifies key step in maturation pathway of telomerase
6. Stowers Institutes Linheng Li Lab expands understanding of bone marrow stem cell niche
7. Stowers Institutes Workman Lab discovers novel histone demethylase protein complex
8. Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health
9. House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss
10. M.I.N.D. Institute researchers call for fragile X testing throughout the lifespan
11. EPA teams with National Geographic Society and World Resources Institute to map ecosystem services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/4/2016)... OXFORD, England , February 4, 2016 ... Advanced Bioscience Laboratories (ABL), Inc. --> Strasbourg, ... (ABL), Inc. --> PharmaVentures is pleased to announce ... sale of its biopharmaceutical manufacturing unit in Strasbourg, ... (ABL), Inc. --> --> ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
Breaking Biology Technology: